Multicenter, Non-comparative Extension to Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2018
At a glance
- Drugs Ponesimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms OPTIMUM-LT
- Sponsors Actelion Pharmaceuticals
- 16 Mar 2018 Planned End Date changed from 31 Mar 2022 to 2 Apr 2022.
- 16 Mar 2018 Planned primary completion date changed from 31 Mar 2022 to 2 Apr 2022.
- 24 Nov 2017 Planned End Date changed from 6 Apr 2022 to 31 Mar 2022.